Genome editing of immune cells using CRISPR/Cas9 |
Kim, Segi
(Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST))
Hupperetz, Cedric (Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST)) Lim, Seongjoon (Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST)) Kim, Chan Hyuk (Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST)) |
1 | Alcantara M, Tesio M, June CH and Houot R (2018) CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells. Leukemia 32, 2307-2315 DOI |
2 | Gomes-Silva D, Srinivasan M, Sharma S et al (2017) CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood 130, 285-296 DOI |
3 | Ren J, Liu X, Fang C, Jiang S, June CH and Zhao Y (2017) Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res 23, 2255-2266 DOI |
4 | Morton LT, Reijmers RM, Wouters AK et al (2020) Simultaneous deletion of endogenous TCRalphabeta for TCR gene therapy creates an improved and safe cellular therapeutic. Mol Ther 28, 64-74 DOI |
5 | Maher J, Brentjens RJ, Gunset G, Riviere I and Sadelain M (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol 20, 70-75 DOI |
6 | Milone MC, Fish JD, Carpenito C et al (2009) Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 17, 1453-1464 DOI |
7 | Uren AG, Kool J, Berns A and van Lohuizen M (2005) Retroviral insertional mutagenesis: past, present and future. Oncogene 24, 7656-7672 DOI |
8 | Niederer HA and Bangham CR (2014) Integration site and clonal expansion in human chronic retroviral infection and gene therapy. Viruses 6, 4140-4164 DOI |
9 | Woods NB, Muessig A, Schmidt M et al (2003) Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis. Blood 101, 1284-1289 DOI |
10 | Eyquem J, Mansilla-Soto J, Giavridis T et al (2017) Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 543, 113-117 DOI |
11 | Rathore A, Iketani S, Wang P, Jia M, Sahi V and Ho DD (2020) CRISPR-based gene knockout screens reveal deubiquitinases involved in HIV-1 latency in two Jurkat cell models. Sci Rep 10, 5350 DOI |
12 | Joung J, Konermann S, Gootenberg JS et al (2017) Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. Nat Protoc 12, 828-863 DOI |
13 | Park RJ, Wang T, Koundakjian D et al (2017) A genomewide CRISPR screen identifies a restricted set of HIV host dependency factors. Nat Genet 49, 193-203 DOI |
14 | Ait-Ammar A, Kula A, Darcis G et al (2019) Current status of latency reversing agents facing the heterogeneity of HIV-1 cellular and tissue reservoirs. Front Microbiol 10, 3060 DOI |
15 | Manganaro L, Pache L, Herrmann T et al (2014) Tumor suppressor cylindromatosis (CYLD) controls HIV transcription in an NF-kappaB-dependent manner. J Virol 88, 7528-7540 DOI |
16 | Tothova Z, Krill-Burger JM, Popova KD et al (2017) Multiplex CRISPR/Cas9-based genome editing in human hematopoietic stem cells models clonal hematopoiesis and myeloid neoplasia. Cell Stem Cell 21, 547-555.e8 DOI |
17 | Wagenblast E, Azkanaz M, Smith SA et al (2019) Functional profiling of single CRISPR/Cas9-edited human long-term hematopoietic stem cells. Nat Commun 10, 4730 DOI |
18 | Cavazzana M, Antoniani C and Miccio A (2017) Gene therapy for beta-hemoglobinopathies. Mol Ther 25, 1142-1154 DOI |
19 | Wu Y, Zeng J, Roscoe BP et al (2019) Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nat Med 25, 776-783 DOI |
20 | Dever DP, Bak RO, Reinisch A et al (2016) CRISPR/Cas9 beta-globin gene targeting in human haematopoietic stem cells. Nature 539, 384-389 DOI |
21 | Zeng J, Wu Y, Ren C et al (2020) Therapeutic base editing of human hematopoietic stem cells. Nat Med 26, 535-541 DOI |
22 | Woods NB, Bottero V, Schmidt M, von Kalle C and Verma IM (2006) Gene therapy: therapeutic gene causing lymphoma. Nature 440, 1123 DOI |
23 | Roth TL, Puig-Saus C, Yu R et al (2018) Reprogramming human T cell function and specificity with non-viral genome targeting. Nature 559, 405-409 DOI |
24 | Wright JF (2008) Manufacturing and characterizing AAV-based vectors for use in clinical studies. Gene Ther 15, 840-848 DOI |
25 | Traxler EA, Yao Y, Wang YD et al (2016) A genome-editing strategy to treat beta-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition. Nat Med 22, 987-990 DOI |
26 | Weber L, Frati G, Felix T et al (2020) Editing a gammaglobin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype. Sci Adv 6, eaay9392 DOI |
27 | Hacein-Bey-Abina S, Garrigue A, Wang GP et al (2008) Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118, 3132-3142 DOI |
28 | Pavel-Dinu M, Wiebking V, Dejene BT et al (2019) Gene correction for SCID-X1 in long-term hematopoietic stem cells. Nat Commun 10, 1634 DOI |
29 | Holt N, Wang J, Kim K et al (2010) Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 28, 839-847 DOI |
30 | Shi B, Li J, Shi X et al (2017) TALEN-mediated knockout of CCR5 confers protection against infection of human immunodeficiency virus. J Acquir Immune Defic Syndr 74, 229-241 DOI |
31 | Xu L, Yang H, Gao Y et al (2017) CRISPR/Cas9-mediated CCR5 ablation in human hematopoietic stem/progenitor cells confers HIV-1 resistance in vivo. Mol Ther 25, 1782-1789 DOI |
32 | Xu L, Wang J, Liu Y et al (2019) CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. N Engl J Med 381, 1240-1247 DOI |
33 | Hartweger H, McGuire AT, Horning M et al (2019) HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells. J Exp Med 216, 1301-1310 DOI |
34 | Roth TL, Li PJ, Blaeschke F et al (2020) Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies. Cell 181, 728-744 e721 DOI |
35 | Klinger M, Benjamin J, Kischel R, Stienen S and Zugmaier G (2016) Harnessing T cells to fight cancer with BiTE(R) antibody constructs--past developments and future directions. Immunol Rev 270, 193-208 DOI |
36 | Guedan S, Ruella M and June CH (2019) Emerging cellular therapies for cancer. Annu Rev Immunol 37, 145-171 DOI |
37 | Strecker J, Ladha A, Gardner Z et al (2019) RNA-guided DNA insertion with CRISPR-associated transposases. Science 365, 48-53 DOI |
38 | Klompe SE, Vo PLH, Halpin-Healy TS and Sternberg SH (2019) Transposon-encoded CRISPR-Cas systems direct RNA-guided DNA integration. Nature 571, 219-225 DOI |
39 | Pan D, Kobayashi A, Jiang P et al (2018) A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science 359, 770-775 DOI |
40 | Nguyen DN, Roth TL, Li PJ et al (2020) Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency. Nat Biotechnol 38, 44-49 DOI |
41 | Pickar-Oliver A and Gersbach CA (2019) The next generation of CRISPR-Cas technologies and applications. Nat Rev Mol Cell Biol 20, 490-507 DOI |
42 | Sander JD and Joung JK (2014) CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 32, 347-355 DOI |
43 | Blank CU, Haining WN, Held W et al (2019) Defining 'T cell exhaustion'. Nat Rev Immunol 19, 665-674 DOI |
44 | Schuster SJ, Svoboda J, Chong EA et al (2017) Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med 377, 2545-2554 DOI |
45 | Neelapu SS, Locke FL, Bartlett NL et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377, 2531-2544 DOI |
46 | Maude SL, Laetsch TW, Buechner J et al (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378, 439-448 DOI |
47 | Wherry EJ and Kurachi M (2015) Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 15, 486-499 DOI |
48 | Choi BD, Yu X, Castano AP et al (2019) CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. J Immunother Cancer 7, 304 DOI |
49 | Hu W, Zi Z, Jin Y et al (2019) CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions. Cancer Immunol Immunother 68, 365-377 DOI |
50 | Rupp LJ, Schumann K, Roybal KT et al (2017) CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep 7, 737 DOI |
51 | Su S, Hu B, Shao J et al (2016) CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients. Sci Rep 6, 20070 DOI |
52 | Henriksson J (2019) CRISPR screening in single cells. Methods Mol Biol 1979, 395-406 DOI |
53 | Kadoch C and Crabtree GR (2015) Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics. Sci Adv 1, e1500447 DOI |
54 | Singh N, Lee YG, Shestova O et al (2020) Impaired death receptor signaling in leukemia causes antigen- independent resistance by inducing CAR T-cell dysfunction. Cancer Discov 10, 552-567 DOI |
55 | Cortez JT, Montauti E, Shifrut E et al (2020) CRISPR screen in regulatory T cells reveals modulators of Foxp3. Nature 582, 416-420 DOI |
56 | Klein AM, Mazutis L, Akartuna I et al (2015) Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells. Cell 161, 1187-1201 DOI |
57 | Macosko EZ, Basu A, Satija R et al (2015) Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell 161, 1202-1214 DOI |
58 | Dixit A, Parnas O, Li B et al (2016) Perturb-Seq: dissecting molecular circuits with scalable single-cell RNA profiling of pooled genetic screens. Cell 167, 1853-1866. e17 DOI |
59 | Tong S, Moyo B, Lee CM, Leong K and Bao G (2019) Engineered materials for in vivo delivery of genome-editing machinery. Nat Rev Mater 4, 726-737 DOI |
60 | Anzalone AV, Koblan LW and Liu DR (2020) Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol 38, 824-844 DOI |
61 | Ishino Y, Shinagawa H, Makino K, Amemura M and Nakata A (1987) Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme convertsion in Escherichia coli, and identification of the gene product. J Bacteriol 169, 5429-5433 DOI |
62 | Jansen R, Embden JD, Gaastra W and Schouls LM (2002) Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol 43, 1565-1575 DOI |
63 | Mojica FJ, Diez-Villasenor C, Garcia-Martinez J and Soria E (2005) Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J Mol Evol 60, 174-182 DOI |
64 | Mardis ER (2017) DNA sequencing technologies: 2006-2016. Nat Protoc 12, 213-218 DOI |
65 | Zhang W, Mitchell LA, Bader JS and Boeke JD (2020) Synthetic genomes. Annu Rev Biochem 89, 77-101 DOI |
66 | Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA and Charpentier E (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821 DOI |
67 | Barrangou R, Fremaux C, Deveau H et al (2007) CRISPR provides acquired resistance against viruses in prokaryotes. Science 315, 1709-1712 DOI |
68 | Mojica FJM, Diez-Villasenor C, Garcia-Martinez J and Almendros C (2009) Short motif sequences determine the targets of the prokaryotic CRISPR defence system. Microbiology (Reading) 155, 733-740 DOI |
69 | Makarova KS, Wolf YI, Iranzo J et al (2020) Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants. Nat Rev Microbiol 18, 67-83 DOI |
70 | Wang H, La Russa M and Qi LS (2016) CRISPR/Cas9 in genome editing and beyond. Annu Rev Biochem 85, 227-264 DOI |
71 | Ren J and Zhao Y (2017) Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9. Protein Cell 8, 634-643 DOI |
72 | Kim S, Kim D, Cho SW, Kim J and Kim JS (2014) Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res 24, 1012-1019 DOI |
73 | Hendel A, Bak RO, Clark JT et al (2015) Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol 33, 985-989 DOI |
74 | McFaline-Figueroa JL, Hill AJ, Qiu X, Jackson D, Shendure J and Trapnell C (2019) A pooled single-cell genetic screen identifies regulatory checkpoints in the continuum of the epithelial-to-mesenchymal transition. Nat Genet 51, 1389-1398 DOI |
75 | Hornung V and Latz E (2010) Intracellular DNA recognition. Nat Rev Immunol 10, 123-130 DOI |
76 | Geering B and Fussenegger M (2015) Synthetic immunology: modulating the human immune system. Trends Biotechnol 33, 65-79 DOI |
77 | Wei SC, Duffy CR and Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8, 1069-1086 DOI |
78 | Jaitin DA, Weiner A, Yofe I et al (2016) Dissecting immune circuits by linking CRISPR-pooled screens with single-cell RNA-Seq. Cell 167, 1883-1896.e15 DOI |
79 | Datlinger P, Rendeiro AF, Schmidl C et al (2017) Pooled CRISPR screening with single-cell transcriptome readout. Nat Methods 14, 297-301 DOI |
80 | Adamson B, Norman TM, Jost M et al (2016) A multiplexed single-cell CRISPR screening platform enables systematic dissection of the unfolded protein response. Cell 167, 1867-1882.e21 DOI |
81 | Chopin M, Lun AT, Zhan Y et al (2019) Transcription factor PU.1 promotes conventional dendritic cell identity and function via induction of transcriptional regulator DC-SCRIPT. Immunity 50, 77-90.e5 DOI |
82 | Haapaniemi E, Botla S, Persson J, Schmierer B and Taipale J (2018) CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response. Nat Med 24, 927-930 DOI |
83 | Cullot G, Boutin J, Toutain J et al (2019) CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations. Nat Commun 10, 1136 DOI |
84 | Xie S, Duan J, Li B, Zhou P and Hon GC (2017) Multiplexed engineering and analysis of combinatorial enhancer activity in single cells. Mol Cell 66, 285-299.e5 DOI |
85 | Webber BR, Lonetree CL, Kluesner MG et al (2019) Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nature Communications 10, 5222 DOI |
86 | Moffett HF, Harms CK, Fitzpatrick KS, Tooley MR, Boon-yaratanakornkit J and Taylor JJ (2019) B cells engineered to express pathogen-specific antibodies protect against infection. Sci Immunol 4, eaax0644 DOI |
87 | Yamada A, Arakaki R, Saito M, Kudo Y and Ishimaru N (2017) Dual role of Fas/FasL-mediated signal in peripheral immune tolerance. Front Immunol 8, 403 DOI |
88 | Stadtmauer EA, Fraietta JA, Davis MM et al (2020) CRISPR-engineered T cells in patients with refractory cancer. Science 367, eaba7365 DOI |
89 | Yang L, Pang Y and Moses HL (2010) TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 31, 220-227 DOI |
90 | Tang N, Cheng C, Zhang X et al (2020) TGF-beta inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight 5, e133977 DOI |
91 | Ren J, Zhang X, Liu X et al (2017) A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget 8, 17002-17011 DOI |
92 | Riese MJ, Moon EK, Johnson BD and Albelda SM (2016) Diacylglycerol kinases (DGKs): novel targets for improving T cell activity in cancer. Front Cell Dev Biol 4, 108 |
93 | Jung IY, Kim YY, Yu HS, Lee M, Kim S and Lee J (2018) CRISPR/Cas9-mediated knockout of DGK improves antitumor activities of human T cells. Cancer Res 78, 4692-4703 DOI |
94 | Norelli M, Camisa B, Barbiera G et al (2018) Monocytederived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 24, 739-748 DOI |
95 | Sterner RM, Sakemura R, Cox MJ et al (2019) GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood 133, 697-709 DOI |
96 | Tian X, Gu T, Patel S, Bode AM, Lee MH and Dong Z (2019) CRISPR/Cas9 - an evolving biological tool kit for cancer biology and oncology. NPJ Precis Oncol 3, 8 DOI |
97 | Teachey DT, Lacey SF, Shaw PA et al (2016) Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 6, 664-679 DOI |
98 | McManus MT and Sharp PA (2002) Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 3, 737-747 DOI |
99 | Jackson AL and Linsley PS (2010) Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 9, 57-67 DOI |
100 | Munoz DM, Cassiani PJ, Li L et al (2016) CRISPR screens provide a comprehensive assessment of cancer vulnerabilities but generate false-positive hits for highly amplified genomic regions. Cancer Discov 6, 900-913 DOI |
101 | Wang T, Wei JJ, Sabatini DM and Lander ES (2014) Genetic screens in human cells using the CRISPR-Cas9 system. Science 343, 80-84 DOI |
102 | Mali P, Aach J, Stranges PB et al (2013) CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol 31, 833-838 DOI |
103 | Perez-Pinera P, Kocak DD, Vockley CM et al (2013) RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods 10, 973-976 DOI |
104 | Konermann S, Brigham MD, Trevino AE et al (2015) Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517, 583-588 DOI |
105 | Zalatan JG, Lee ME, Almeida R et al (2015) Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds. Cell 160, 339-350 DOI |
106 | Gilbert LA, Larson MH, Morsut L et al (2013) CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154, 442-451 DOI |
107 | McDade JR, Waxmonsky NC, Swanson LE and Fan M (2016) Practical considerations for using pooled lentiviral CRISPR libraries. Curr Protoc Mol Biol 115, 31.5.1-31.5.13 |